TLCD1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: TLCD1

NCBI ID: G116238

TLCD1

TLCD1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

TLCD1 (TLC domain-containing protein 1) is a protein that has been identified using a bioinformatics analysis as having potential therapeutic properties for neurodegenerative diseases. This protein is located within the TLC (transmembrane carboxylate) domain and is involved in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling pathways.

The TLC domain is a conserved region that is found in various proteins, including TLCD1, that play a crucial role in the regulation of protein function and interactions. This region is known for its ability to form a disulfide bond, which can modulate the conformation and activity of the protein.

TLCD1: A Potential Drug Target

TLCD1 has been shown to be involved in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the formation of aggregates of misfolded proteins, which can lead to the development of neurodegeneration.

One of the key features of TLCD1 is its ability to interact with other proteins that are involved in the development and progression of neurodegenerative diseases. For example, studies have shown that TLCD1 can interact with the protein huntingtin, which is known to be involved in the development of neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, TLCD1 has also been shown to be involved in various signaling pathways that are involved in cell growth, differentiation, and survival. This suggests that TLCD1 may be a drug target that can be used to treat these conditions.

TLCD1: A Potential Biomarker

In addition to its potential role as a drug target, TLCD1 has also been shown to be involved in the development of various types of cancer. This suggests that it may be a useful biomarker for the early detection of cancer.

Studies have shown that TLCD1 can be expressed in various types of cancer cells, including breast, lung, and ovarian cancer cells. This suggests that TLCD1 may be a useful biomarker for the detection and treatment of cancer.

Conclusion

TLCD1 is a protein that has been identified using bioinformatics analysis as having potential therapeutic properties for neurodegenerative diseases. This protein is involved in various cellular processes and has been shown to be involved in the development and progression of these conditions.

In addition to its potential role as a drug target, TLCD1 has also been shown to be involved in the development of various types of cancer. This suggests that it may be a useful biomarker for the early detection of cancer.

Therefore, TLCD1 is a protein that has the potential to be a valuable drug target and biomarker for the treatment of neurodegenerative diseases and cancer. Further research is needed to fully understand the role of TLCD1 in these conditions and to develop effective treatments.

Protein Name: TLC Domain Containing 1

Functions: Regulates the composition and fluidity of the plasma membrane (PubMed:30509349). Inhibits the incorporation of membrane-fluidizing phospholipids containing omega-3 long-chain polyunsaturated fatty acids (LCPUFA) and thereby promotes membrane rigidity (PubMed:30509349). Does not appear to have any effect on LCPUFA synthesis (PubMed:30509349)

The "TLCD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLCD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets